Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.

Thorac Cancer · 2019 · PMC6449246 · PMID 30734504

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might not be significantno p-value reported

First, the difference in the mutational burden between squamous and non‐squamous NSCLC might not be significant.

also in 673 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.